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THE ROLE OF POST GRANULOCYTE COLONY-STIMULATING FACTOR
WHITE BLOOD CELL COUNTS IN PREDICTING THE MOBILIZATION AD-
VERSE EVENTS AND YIELDS
Wang, T.-F.1,2, Chen, S.-H.2,3, Chang, C.-Y.2, Yang, S.-H.2,3, Su, Y.-
C.4, Chu, S.-C.1, Yang, K.-L.2 1Buddhist Tzu-Chi General Hospital,
Hualien, Taiwan; 2Buddhist Tzu-Chi Stem Cell Center, Hualien,
Taiwan; 3Buddhist Tzu-Chi General Hospital, Hualien, Taiwan;
4Buddhist Tzu-Chi General Hospital, Cha-Yi, Taiwan
Background: To evaluate the incidences of adverse events of gran-
ulocyte colony-stimulating factor (G-CSF) and the impacts of post
G-CSF white blood cell (WBC) counts on adverse events and mobi-
lization yields in healthy peripheral blood stem cell donors.
Materials and Methods: Four hundred seventy-six healthy donors
were given G-CSF of 10mg/kg/day for 5-6 consecutive days. The
WBC counts were determinated at baseline, after third dose (before
the forth dose on Day4) and after fifth dose (before leukapheresis on
Day5) of G-CSF administration. Performance status and symptoms
were recorded everyday beforeG-CSF injection. The incidences of ad-
verse events and mobilization yields were compared between different
donor characteristic groups. Multivariate analysis was used to analyze
the correlations between the adverse events and donor factors.
Results: Bone pain (64.9%), myalgia/arthralgia (58.2%), fatigue
(44.1%) and headache (33.0%) were the most common side effects.
The third day and fifth day median WBC counts were 35,050/mL
and 45,905/mL. Donors with WBC $ 50x103/mL after 3 doses of
G-CSF experienced more fatigue, myalgia/arthralgia and chills (p
5 0.0314, 0.0066 and 0.0121) but post G-CSF CD34+ cells were
similar (72.6/mL vs 68.7/mL, p 5 0.5916). Although the CD34+ cells
were higher in donors with WBC $ 50x103/mL after 5 doses of G-
CSF (89.3/mL vs 59.1/mL, p\0.0001), the incidences of side effects
were similar. Female donors more frequently had headache, nausea/
anorexia, vomiting, fever (p 5 0.003,\ 0.0001, 0.0016 and 0.0392)
and lower post G-CSF CD34+ cell count than male donors did
(78.0/mL vs 59.0/mL, p\ 0.0001). Donors with body mass index $
25 had higher incidences of sweat and insomnia (p 5 0.0211 and
0.0318) and also higher CD34+ cell count (79.9/mL vs 64.9/mL, p
\ 0.0001). Donor receiving G-CSF $ 10mg/kg tended to have
bone pain, headache and chills (p 5 0.0085, 0.0270 and 0.0085).
The side effects and CD34+ cells were not different between young
and old donors.
In multivariate analysis, female donor experienced more fatigue,
nausea, vomiting, bone pain, myalgia/arthragia, headache, fever
and insomnia. Higher BMI donor had more fatigue, myalgia/arthra-
gia and sweats. G-CSF dose was associated with bone pain and the
WBC count post the third G-CSF was associated with fatigue only.
Conclusion: Female and high BMI donors are associated with
higher risk of side effects of PBSC mobilization by G-CSF. Routine
monitor of the post G-CSF WBC count provide minimal benefit in
predicting side effects. Reducing dose or discontinuation of G-CSF
should mainly base on the clinical severity of adverse events.
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AFFECT OF CARDIAC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION FROM VARIOUS STEM CELL
SOURCES
Nishinohara, M., Kobayashi, K., Maeda, Y., Shinagawa, K.,
Tanimoto, M. Okayama University Hospital, Okayama, Okayama, Japan
Background: Cardiac complications after Allogenic Hematopoietic
Stem Cell Transplantation (allo-SCT) have varied among studies.
Furthermore, various stem cell sources have increasingly been used
as a therapeutic option, it remains unknown the affect of cardiac
complications after allo-SCT from various stem cell sources.
Patients and Methods: We retrospectively reviewed 172 patients
underwent allo-SCT at Okayama University Hospital between
May 2004 and October 2010, for whom electrocardiography
(ECG) and ultrasound cardiography (UCG) within 3 months before
transplantation. The median age at allo-SCT was 50 years (range:
16-74). Donor sources were related peripheral blood in 41, related
bone marrow in 13 and unrelated bone marrow in 66, and umbilical
cord blood in 52 cases, respectively. 80 (46.5%) patients had high risk
disease at the time of transplantation.Results:We identified 31 patients (18%) with grade 2-4 cardiac com-
plications within 28 days after allo-SCT according to the Common
Terminology Criteria for Adverse Events v3.0 (CTCAE). 4 patients
(0.02%) developed grade 3-4 cardiac complications. The median
time of onset after allo-SCT was 9 days (range: -7-23 days). Manifes-
tation of cardiac complications was mainly pulmonary congestion in
19, while hypertension in 5, arrhythmia in 3, pericardial effusion in
2, cardiac ischemia in 1 and hypotension in 1 case, respectively. 2 pa-
tients died of cardiac causes after the onset of severe cardiac complica-
tions. The cumulative 1-year overall survival in patients with or
without cardiac complication was 46.8% and 57.2%, respectively (p
5 0.29). There was no difference in the ECG/UCG findings, the cu-
mulative dose of anthracyclines and between patients with and without
cardiac complications. Furthermore, no difference in rate of cardiac
complications was observed in among stem cell sources.
Conclusion: Although from a retrospective study, these results sug-
gest that cardiac complications were associated with relatively poor
survival but not with stem cell sources although this finding must
be considered with caution due to the small sample size.
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LINEAGE-SPECIFIC CHIMERISM ANALYSIS IS A SENSITIVE PREDICTOR OF
OUTCOME AFTER ALLOGENEIC MYELOABLATIVE AND NONMYELOABLA-
TIVE STEM CELL TRANSPLANTATION
Saracino, G.1,2, Agura, E.1,2,3, Berryman, B.1,2,3, Fay, J.1,2,3,
Pineiro, L.1,2,3, Vance, E.1,2,3, Saad, R.1 1Baylor University Medical Cen-
ter, Dallas, TX; 2Charles A. Sammons Cancer Center, Dallas, TX;
3Texas Oncology PA, Dallas, TX
Monitoring chimerism in allogeneic hematopoietic stem cell
transplant (HSCT) recipients is of great clinical significance after
different conditioning regimens. Analysis of lineage-specific leuko-
cytes provides useful information in predicting the clinical outcome
and plays a critical role in the management of HSCT patient. We
have analyzed donor-type chimerism in CD3+ T cells, CD19+ B
cells, CD15 + myeloid cells and CD34+ progenitor cells in patients
who had undergone myeloablative and nonmyeloablative HSCT
for acute myeloid leukemia (AML) and non-AML. The engraftment
analysis was performed by PCR-based detection of donor- and recip-
ient-specific short tandem repeats (STR) using enriched T cells, my-
eloid cells, B cells and progenitor cells from peripheral blood and
bonemarrow samples prior to isolation of DNA. Chimerism analysis
performed onCD34+ progenitor cells wasmost useful in early detec-
tion of relapse in AML patients than unfractionated whole blood
analysis due the increased sensitivity in the enriched cell subpopula-
tions. Monitoring of leukemia- and lymphoma-affected cell lineage
predicted relapse. Determination of the level of donor T cells ap-
pears to be critical for successful engraftment and predict graft versus
host disease in transplant patients who underwent nonmyeloablative
HSCT. Donor-type chimerism in lineage-specific cell population
appears to impact outcome and allows early intervention.
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SAFETY OF LIPOSOMAL AMPHOTERICIN B IN ALLOGENIC HEMATOPOI-
ETIC TRANSPLANTATION (HSCT) RECIPIENTS
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Ishiwata, K.1, Araoka, H.2, Tsuji, M.1, Yamamoto, H.1, Asano-
Mori, Y.1, Izutsu, K.1, Uchida, N.1, Yoneyama, A.2, Wake, A.3,
Makino, S.4, Taniguchi, S.1 1Toranomon Hospital, Tokyo, Japan;
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In the patients performed HSCT, liposomal amphotericin B (L-
AMB) is one of useful antifungal agents because of its broad-spec-
trum. However, little was known about the safety of L-AMB in
allogenic HSCT setting. There were 90 patients administrated L-
AMB around allogenic HSCT in our institute from December
2007 to November 2009 consecutively. Thirty-two of those 90 pa-
tients were administrated L-AMB at least for 1 week during in day
-30 to 120 after HSCT. We analyzed those 32 patients, included
23 males and 9 females, retrospectively. Median age was 58 (29-68)
yrs. Stem cell sources of HSCT were 22 CB, 7 unrelated BM and
3 sibling-PB respectively. Two patients used L-AMB as prevention
to invasive fungal infections (IFIs) and 30 treatment. Thirty-one pa-
tients received other prior anti-fungal therapies. Median follow up
period from the day starting L-AMB was 71.5 (7-466) days. Median
